ArticleAnnals of clinical and translational neurology2024

Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.

Daiki Tokuyasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.